DISCLAIMER: The information on this site is intended for healthcare professionals only.
With the exception of TLX591-CDx in the United States, Australia, and Canada, none of Telix’s products has received a marketing authorisation in any jurisdiction.
PHASE III CHINA REGISTRATION STUDY FOR ILLUCCIX
China Registration Study for Illuccix (Phase III)
Study title:68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
Study description: This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA after radical prostatectomy or radical radiotherapy. This study investigates how well 68Ga-PSMA-11 PET/CT works in detecting BCR prostate cancer in Chinese patient. 68Ga-PSMA-11, developed by Telix, is a new molecular entity tracer with the trade name Illuccix®, which is approved by FDA for the examination of: 1) patients with suspected metastatic PC who are scheduled for initial treatment; 2) patients with biochemical recurrence of elevated PSA levels after initial radical radiotherapy.
A study investigating how well 68Ga-PSMA-11 PET/CT works in detecting BCR prostate cancer in Chinese patients.
ELIGIBILITY: INCLUSION CRITERIA
Are able to understand and provide written informed consent document.
Are Chinese males aged ≥ 18 years.
Have histopathologically confirmed prostate adenocarcinoma and have undergone radical prostatectomy and/or radical radiotherapy and experienced biochemical recurrence (PSA should be measured within 30 days of screening).
Post radical prostatectomy (RP) PSA ≥0.2 ng/mL measured 6 weeks after RP
Post radiation therapy – ASTRO-Phoenix consensus definition Nadir + ≥ 2 ng/mL rise in PSA;
Have a Karnofsky performance status ≥ 60 (or ECOG/WHO equivalent).
Agree to practice a highly effective method of contraception for at least 28 days after 68Ga-PSMA-11 administration.
Are willing and able to comply with scheduled
ELIGIBILITY: EXCLUSION CRITERIA
Have a prior history of any other malignancy within the last year, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.
Have prior use of radionuclides with an interval of less than 10 physical half-lives before the administration of 68Ga-PSMA-11.
Are participating or plan to participate in any drug or device clinical study during the study period.
Have a known hypersensitivity to the active ingredient or its components of 68Ga-PSMA-11.
Cannot lie flat or remain still while a PET scan is being performed or cannot tolerate a PET scan.
Have prior history of salivary gland disease or Paget’s disease.
Have a history of fracture and anemia within the last year.
Have abnormalities in physical examination, ECG, and protocol-specified clinical laboratory tests during the Screening Period that, in the judgment of the investigator, could affect safety or compliance.
Is deemed not suitable for participating in this trial in the opinion of the investigator.
Welcome to themightywonton.net.au/wp-telix.
This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in diagnosis, medical research and ongoing clinical trials in relation to radiopharmaceutical diagnostic and therapeutic (‘theranostic’) approaches. It is intended only for healthcare professionals.
This link will bring you to a third party website, owned and operated by an independent party over which Telix has no control.
Do you wish to continue?